JP2007509117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509117A5 JP2007509117A5 JP2006536168A JP2006536168A JP2007509117A5 JP 2007509117 A5 JP2007509117 A5 JP 2007509117A5 JP 2006536168 A JP2006536168 A JP 2006536168A JP 2006536168 A JP2006536168 A JP 2006536168A JP 2007509117 A5 JP2007509117 A5 JP 2007509117A5
- Authority
- JP
- Japan
- Prior art keywords
- thiazol
- pyrimidin
- dimethyl
- phenylamino
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(N1*)=C(c2nc(N*)nc(C)c2*)SC1=O Chemical compound CC(N1*)=C(c2nc(N*)nc(C)c2*)SC1=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0324599A GB0324599D0 (en) | 2003-10-21 | 2003-10-21 | Compound |
| GB0324599.0 | 2003-10-21 | ||
| GB0330013.4 | 2003-12-23 | ||
| GB0330013A GB0330013D0 (en) | 2003-12-24 | 2003-12-24 | Compound |
| PCT/GB2004/004465 WO2005042525A1 (en) | 2003-10-21 | 2004-10-21 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509117A JP2007509117A (ja) | 2007-04-12 |
| JP2007509117A5 true JP2007509117A5 (enExample) | 2007-12-06 |
| JP5164380B2 JP5164380B2 (ja) | 2013-03-21 |
Family
ID=34553788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536168A Expired - Fee Related JP5164380B2 (ja) | 2003-10-21 | 2004-10-21 | ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7902361B2 (enExample) |
| EP (1) | EP1678171B1 (enExample) |
| JP (1) | JP5164380B2 (enExample) |
| AU (1) | AU2004285745A1 (enExample) |
| BR (1) | BRPI0415759A (enExample) |
| CA (1) | CA2542880A1 (enExample) |
| IL (1) | IL174994A0 (enExample) |
| WO (1) | WO2005042525A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
| GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| GB0226582D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| JP2007514759A (ja) | 2003-12-19 | 2007-06-07 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| CA2576159A1 (en) * | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EP1951307A2 (en) * | 2005-11-11 | 2008-08-06 | Cyclacel Limited | Combination of a cdk-inhibitor and a hdac-inhibitor |
| CN101365700A (zh) | 2005-11-15 | 2009-02-11 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氮杂吲唑 |
| US7504513B2 (en) | 2006-02-27 | 2009-03-17 | Hoffman-La Roche Inc. | Thiazolyl-benzimidazoles |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| BRPI0719883A2 (pt) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| CN102256972A (zh) | 2008-12-18 | 2011-11-23 | 霍夫曼-拉罗奇有限公司 | 噻唑基-苯并咪唑类 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
| WO2014069434A1 (ja) * | 2012-10-30 | 2014-05-08 | カルナバイオサイエンス株式会社 | 新規チアゾリジノン誘導体 |
| EP3206749B1 (en) | 2014-10-14 | 2021-09-08 | The Regents of the University of California | The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation |
| CN113336746A (zh) | 2015-08-04 | 2021-09-03 | 常州千红生化制药股份有限公司 | N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物 |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2025151517A1 (en) | 2024-01-08 | 2025-07-17 | Wavebreak Therapeutics Limited | Thiazole compounds, compositions and methods of treating disorders associated with missfolding of alpha-synuclein protein |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9519275D0 (en) | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US6962792B1 (en) | 1996-05-08 | 2005-11-08 | Cyclacel Limited | Methods and means for inhibition of Cdk4 activity |
| US6221873B1 (en) | 1998-03-04 | 2001-04-24 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US6703395B2 (en) | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| HUP0300382A3 (en) | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| DE60217140T2 (de) * | 2001-09-28 | 2007-04-19 | Cyclacel Ltd. | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen |
| JP4570955B2 (ja) * | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0226582D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
-
2004
- 2004-10-21 BR BRPI0415759-1A patent/BRPI0415759A/pt not_active IP Right Cessation
- 2004-10-21 WO PCT/GB2004/004465 patent/WO2005042525A1/en not_active Ceased
- 2004-10-21 CA CA002542880A patent/CA2542880A1/en not_active Abandoned
- 2004-10-21 AU AU2004285745A patent/AU2004285745A1/en not_active Abandoned
- 2004-10-21 JP JP2006536168A patent/JP5164380B2/ja not_active Expired - Fee Related
- 2004-10-21 EP EP04768981.5A patent/EP1678171B1/en not_active Expired - Lifetime
-
2006
- 2006-04-11 IL IL174994A patent/IL174994A0/en unknown
- 2006-04-21 US US11/408,463 patent/US7902361B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509117A5 (enExample) | ||
| JP2007520540A5 (enExample) | ||
| JP2007500178A5 (enExample) | ||
| JP2008526824A5 (enExample) | ||
| CN1158269C (zh) | 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物 | |
| JP2013517283A5 (enExample) | ||
| US7915443B2 (en) | Sulfoximines as kinase inhibitors | |
| RU2469036C2 (ru) | Имидазопиридиновые ингибиторы киназ | |
| JP4988355B2 (ja) | 置換ピペラジン | |
| JP2008500320A5 (enExample) | ||
| CN1124269C (zh) | 取代的嘧啶化合物和其用途 | |
| JP2014511869A5 (enExample) | ||
| US20070021419A1 (en) | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
| JP2007504160A5 (enExample) | ||
| JP2006519258A5 (enExample) | ||
| JP2008517945A5 (enExample) | ||
| US20050288307A1 (en) | Anti-viral compounds | |
| CN1395566A (zh) | 促肾上腺皮质激素释放因子拮抗剂 | |
| JP2013510876A5 (enExample) | ||
| CN1592743A (zh) | 糖元合成酶激酶3的抑制剂 | |
| JP2017526711A5 (enExample) | ||
| JP2010215644A5 (enExample) | ||
| BG65029B1 (bg) | Триазолови съединения и използването им като допамин-d3-лиганди | |
| CN1642931A (zh) | 用作新颖的组蛋白去乙酰酶抑制剂的磺酰基衍生物 | |
| CN1656073A (zh) | 可用于治疗蛋白激酶依赖性疾病的二芳基脲衍生物 |